Trevi Therapeutics, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jennifer L. Good
- Full Time Employees
- 31
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 195 Church Street New Haven CT United States of America 06510
- IPO Date
- May 7, 2019
- CIK
- 0001563880
- Website
- trevitherapeutics.com
- Similar Companies
- Business
- Trevi Therapeutics, Inc. (Nasdaq: TRVI) is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders associated with the defective corticotropin-releasing factor (CRF) signaling pathway; its lead candidate, hadrava (Spinosad GRAS), is a topical formulation in Phase 3 development for the treatment of head lice infestation, while additional pipeline assets target other parasitic conditions with unmet needs. The company offers proprietary platforms for topical neuroactive compounds, including gamma-aminobutyric acid type A (GABAA) receptor modulators for epilepsy and essential tremor, and selective sodium channel blockers for neuropathic pain. Founded in 2018 and headquartered in New Haven, Connecticut, Trevi operates primarily in the United States with clinical trials conducted globally across North America, Europe, and other regions, targeting pediatric and adult patients in dermatology and neurology segments. In recent developments within the last year, Trevi Therapeutics completed enrollment in its Phase 3 CENTAUR trial for hadrava in head lice in mid-2025, positioning it for potential regulatory submission; the company also reported positive topline results from the Phase 2b SPARTAN trial for its GABAA candidate in essential tremor in late 2024, advancing its pipeline expansion; additionally, Trevi announced a strategic licensing agreement in early 2025 to expand hadrava's formulation for scabies treatment, alongside a $50 million financing round to support ongoing Phase 3 programs.
Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters.
Trevi Therapeutics, Inc. (TRVI) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
Trevi Therapeutics Maps Haduvio Chronic Cough Push, Sees Cash Runway Into 2030
Trevi Therapeutics, Inc. (TRVI) Q1 2026 Earnings Call Transcript
Trevi Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
Trevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International Conference
Trevi Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 5, 2026
Trevi Therapeutics to Participate in Upcoming May Events
Trevi Therapeutics Announces Closing of $173 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
What's Going On With Trevi Therapeutics Stock?
Trevi Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock
Trevi Therapeutics Announces Proposed Public Offering of Common Stock
SG Americas Securities LLC Has $1.56 Million Stock Position in Trevi Therapeutics, Inc. $TRVI
Trevi Therapeutics to Participate in Upcoming Events
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Recommendation of “Buy” from Analysts
Head-To-Head Review: Trevi Therapeutics (NASDAQ:TRVI) vs. DNAPrint Genomics (OTCMKTS:DNAG)
Trevi Therapeutics Q4 Earnings Call Highlights
Trevi Therapeutics, Inc. (TRVI) Q4 2025 Earnings Call Transcript
Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates
Atea Pharmaceuticals (NASDAQ:AVIR) vs. Trevi Therapeutics (NASDAQ:TRVI) Financial Survey